Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly ...
Risk Stratification Using Tree-Based Models for Recurrence-Free Survival in Breast Cancer A total of 40.0% of patients received molecular targeted therapy (MTA), including kinase inhibitors and ...
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results